Table 1.

Eligibility criteria

Inclusion criteria	1. Age ≥18 yr
	2. Currently hospitalized or in an emergency department with anticipated hospitalization
	3. Symptoms of acute respiratory infection, defined as one or more of the following:
	a. Cough
	b. Fever (>37.5°C/99.5°F)
	c. Shortness of breath (operationalized as any of the following: subjective shortness of breath reported by patient/surrogate; hypoxemia, defined as SpO2 < 92% on room air or increased oxygen requirement for a patient on chronic oxygen to maintain SpO2 ≥ 92%; tachypnea with respiratory rate ≥22/min).
	d. Sore throat
	4. Laboratory-confirmed SARS-CoV-2 infection within the past 10 d before randomization
Exclusion criteria	1. Prisoner
	2. Pregnancy
	3. Breast feeding
	4. Unable to randomize within 10 d after onset of acute respiratory infection symptoms
	5. Unable to randomize within 48 h after hospital arrival
	6. Seizure disorder
	7. Porphyria cutanea tarda
	8. QTc > 500 ms on electrocardiogram within 72 h before enrollment
	9. Diagnosis of long QT syndrome
	10. Known allergy to hydroxychloroquine, chloroquine, or amodiaquine
	11. Receipt in the 12 h before enrollment or planned administration during the 5-d study period that treating clinicians feel cannot be substituted for another medication of any of the following: amiodarone, cimetidine, dofetilide, phenobarbital, phenytoin, sotalol
	12. Receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 d before enrollment
	13. Inability to receive enteral medications
	14. Refusal or inability to be contacted on Day 15 for clinical outcome assessment if discharged before Day 15
	15. Previous enrollment in this trial
	16. The treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient

Definition of abbreviations: QTc = corrected QT; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Sp_O2 = oxygen saturation as measured by pulse oximetry.